Skip to main content
Top
Published in: Clinical Rheumatology 3/2006

01-05-2006 | Original Article

A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis

Authors: Anna Kuryliszyn-Moskal, Piotr Adrian Klimiuk, Stanisław Sierakowski, Mariusz Ciolkiewicz

Published in: Clinical Rheumatology | Issue 3/2006

Login to get access

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with a wide range of extra-articular manifestations. Recent studies emphasise a key inflammatory role of the endothelial cells, either by overexpression of inflammatory mediators or by the proliferation of new blood vessels, in the disease process leading to the systemic organ involvement. To evaluate the relationship between internal organ manifestations and immunological markers of endothelial activation, serum levels of vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1) were determined by an enzyme-linked immunosorbent assay in 64 RA patients and in 32 healthy controls. In comparison with a control group, higher serum concentrations of VEGF and ET-1 (p<0.001) in RA patients were demonstrated. A comparison between both RA groups with (20 patients) and without systemic involvement (44 patients) showed significantly higher concentrations of VEGF (p<0.05) and ET-1 (p<0.01) in the sera of patients with systemic manifestation. Moreover, a significant positive correlation between VEGF and ET-1 (r=0.475, p<0.001) in RA patients was found. A positive correlation between VEGF and Disease Activity Score (DAS) 28 index (r=0.39, p<0.005) as well as erythrocyte sedimentation rate (ESR) (r=0.564, p<0.0001) and C-reactive protein was found. ET-1 serum level correlated significantly with ESR (r=0.326, p<0.05) and DAS 28 index (r=0.307, p<0.05). These results suggest that the elevated serum levels of VEGF and ET-1 are associated with systemic organ involvement in RA patients and may play a key role in the pathogenesis of extra-articular manifestation of the disease.
Literature
1.
go back to reference Firestein GS (1997) Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology, Saunders, Philadelphia pp 851–897 Firestein GS (1997) Etiology and pathogenesis of rheumatoid arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology, Saunders, Philadelphia pp 851–897
2.
go back to reference Tak PP, Bresnihan B (2000) The pathogenesis and prevention of joint damage in rheumatoid arthritis. Advances from synovial biopsy and tissue analysis. Arthritis Rheum 43:2619–2633CrossRefPubMed Tak PP, Bresnihan B (2000) The pathogenesis and prevention of joint damage in rheumatoid arthritis. Advances from synovial biopsy and tissue analysis. Arthritis Rheum 43:2619–2633CrossRefPubMed
3.
go back to reference Sany J (1995) Clinical and immunopathological extraarticular manifestations of rheumatoid arthritis. Rheumatol Eur 24(suppl):175–178 Sany J (1995) Clinical and immunopathological extraarticular manifestations of rheumatoid arthritis. Rheumatol Eur 24(suppl):175–178
4.
go back to reference Turesson C, Jacobsson LTH (2004) Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 33:65–72CrossRefPubMed Turesson C, Jacobsson LTH (2004) Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 33:65–72CrossRefPubMed
5.
go back to reference Bacon PA, Kitas GD (1994) The significance of vascular inflammation in rheumatoid arthritis. Ann Rheum Dis 53:621–623PubMed Bacon PA, Kitas GD (1994) The significance of vascular inflammation in rheumatoid arthritis. Ann Rheum Dis 53:621–623PubMed
6.
go back to reference Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS (1999) Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 19:91–104CrossRefPubMed Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS (1999) Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 19:91–104CrossRefPubMed
7.
go back to reference Paleolog EM (1996) Angiogenesis: a critical process in the pathogenesis of RA—a role for VEGF? Br J Rheumatol 35:917–920CrossRefPubMed Paleolog EM (1996) Angiogenesis: a critical process in the pathogenesis of RA—a role for VEGF? Br J Rheumatol 35:917–920CrossRefPubMed
8.
go back to reference Koch AE (2000) The role of angiogenesis in rheumatoid arthritis—recent development. Ann Rheum Dis 59:465–471CrossRef Koch AE (2000) The role of angiogenesis in rheumatoid arthritis—recent development. Ann Rheum Dis 59:465–471CrossRef
9.
go back to reference Brenchley PEC (2001) Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis 60:iii71–iii74PubMed Brenchley PEC (2001) Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis 60:iii71–iii74PubMed
10.
go back to reference Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, Ariyoshi M, Saiki T, Sakamoto M, Nagata K, Sata M, Matsuo K, Tanikawa K (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 27:377–380CrossRefPubMed Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, Ariyoshi M, Saiki T, Sakamoto M, Nagata K, Sata M, Matsuo K, Tanikawa K (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 27:377–380CrossRefPubMed
11.
go back to reference Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, Cho CS, Kim HY (2001) Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 19:321–324PubMed Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH, Cho CS, Kim HY (2001) Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 19:321–324PubMed
12.
go back to reference Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J (2002) Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 61:804–809CrossRefPubMed Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J (2002) Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 61:804–809CrossRefPubMed
13.
go back to reference Mayes MD (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48:1190–1199CrossRefPubMed Mayes MD (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48:1190–1199CrossRefPubMed
14.
go back to reference Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S (1995) Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 54:361–365PubMedCrossRef Yoshio T, Masuyama J, Mimori A, Takeda A, Minota S, Kano S (1995) Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 54:361–365PubMedCrossRef
15.
go back to reference Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838–1844PubMed Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838–1844PubMed
16.
go back to reference Haq A, El-Ramahi K, Al-Dalaan A, Al-Sedairy ST (1999) Serum and synovial fluid concentrations of endothelin-1 in patients with rheumatoid arthritis. J Med 30:51–60PubMed Haq A, El-Ramahi K, Al-Dalaan A, Al-Sedairy ST (1999) Serum and synovial fluid concentrations of endothelin-1 in patients with rheumatoid arthritis. J Med 30:51–60PubMed
17.
go back to reference Kuryliszyn-Moskal A, Bernacka K, Klimiuk PA (1996) Circulating intercellular adhesion molecule 1 in rheumatoid arthritis—relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy. Clin Rheumatol 15:367–373CrossRefPubMed Kuryliszyn-Moskal A, Bernacka K, Klimiuk PA (1996) Circulating intercellular adhesion molecule 1 in rheumatoid arthritis—relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy. Clin Rheumatol 15:367–373CrossRefPubMed
18.
go back to reference Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2001) Serum autoantibodies profile and increased levels of circulating intercellular adhesion molecule-1: a reflection of the immunologically mediated systemic vasculopathy in rheumatic diseases? Arch Immunol Ther Exp 49:423–430 Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2001) Serum autoantibodies profile and increased levels of circulating intercellular adhesion molecule-1: a reflection of the immunologically mediated systemic vasculopathy in rheumatic diseases? Arch Immunol Ther Exp 49:423–430
19.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
20.
go back to reference Prevoo MLL, Van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef Prevoo MLL, Van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
21.
go back to reference Szekanecz Z, Szegedi G, Koch AE (1998) Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Investig Med 46:27–41PubMed Szekanecz Z, Szegedi G, Koch AE (1998) Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Investig Med 46:27–41PubMed
22.
go back to reference Koch AE (2003) Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 62 (suppl II):ii60–ii67CrossRefPubMed Koch AE (2003) Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 62 (suppl II):ii60–ii67CrossRefPubMed
23.
go back to reference Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP (2003) Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 48:72–80CrossRefPubMed Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP (2003) Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 48:72–80CrossRefPubMed
24.
go back to reference Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M, Shoenfeld Y, Schillaci G, Mannarino E (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63:31–35CrossRefPubMed Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M, Shoenfeld Y, Schillaci G, Mannarino E (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63:31–35CrossRefPubMed
25.
go back to reference Sundy JS, Haynes BF (1995) Pathogenic mechanisms of vessel damage in vasculitis syndromes. Rheum Dis Clin North Am 21:861–881PubMed Sundy JS, Haynes BF (1995) Pathogenic mechanisms of vessel damage in vasculitis syndromes. Rheum Dis Clin North Am 21:861–881PubMed
26.
go back to reference Verschueren PC, Voskuyl AE, Smeets TJ, Zwinderman KH, Breedveld FC, Tak PP (2000) Increased cellularity and expression of adhesion molecules in muscle biopsy specimens from patients with rheumatoid arthritis with clinical suspicion of vasculitis, but negative routine histology. Ann Rheum Dis 59:598–606CrossRefPubMed Verschueren PC, Voskuyl AE, Smeets TJ, Zwinderman KH, Breedveld FC, Tak PP (2000) Increased cellularity and expression of adhesion molecules in muscle biopsy specimens from patients with rheumatoid arthritis with clinical suspicion of vasculitis, but negative routine histology. Ann Rheum Dis 59:598–606CrossRefPubMed
27.
go back to reference DeMaria AN (2002) Relative risk of cardiovascular events in patients with rheumatoid arthritis. J Cardiol 89(suppl):33d–38d DeMaria AN (2002) Relative risk of cardiovascular events in patients with rheumatoid arthritis. J Cardiol 89(suppl):33d–38d
28.
go back to reference Manzi S, Waasko MC (2000) Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 59:321–325CrossRefPubMed Manzi S, Waasko MC (2000) Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 59:321–325CrossRefPubMed
29.
go back to reference Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1297–1301CrossRefPubMed Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1297–1301CrossRefPubMed
30.
go back to reference Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J (2001) Circulating activated endothelial cells in systemic lupus erythematosus. Further evidence for diffuse vasculopathy. Arthritis Rheum 44:1203–1208CrossRefPubMed Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J (2001) Circulating activated endothelial cells in systemic lupus erythematosus. Further evidence for diffuse vasculopathy. Arthritis Rheum 44:1203–1208CrossRefPubMed
31.
go back to reference Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K (1998) Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 139:1049–1051CrossRefPubMed Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K (1998) Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 139:1049–1051CrossRefPubMed
32.
go back to reference Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527–543PubMedCrossRef Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527–543PubMedCrossRef
33.
go back to reference Kasama T, Shiozawa F, Kobayashi K, Yajima N, Hanyuda M, Takeuchi HT, Mori Y, Negishi M, Ide H, Adachi M (2001) Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis. Arthritis Rheum 44:2512–2524CrossRefPubMed Kasama T, Shiozawa F, Kobayashi K, Yajima N, Hanyuda M, Takeuchi HT, Mori Y, Negishi M, Ide H, Adachi M (2001) Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis. Arthritis Rheum 44:2512–2524CrossRefPubMed
34.
go back to reference Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41:1258–1265CrossRefPubMed Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41:1258–1265CrossRefPubMed
35.
go back to reference Mayes MD (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48:1190–1199CrossRefPubMed Mayes MD (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48:1190–1199CrossRefPubMed
36.
go back to reference Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM (1998) Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 31 (suppl 1):S360–S363CrossRefPubMed Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM (1998) Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol 31 (suppl 1):S360–S363CrossRefPubMed
37.
go back to reference Matsuda J, Tsukamoto M, Gohchi K, Saitoh N, Miyajima Y, Kazama M (1992) Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon. Acta Haematol 88:189–193PubMed Matsuda J, Tsukamoto M, Gohchi K, Saitoh N, Miyajima Y, Kazama M (1992) Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon. Acta Haematol 88:189–193PubMed
38.
go back to reference Filep JG, Bodolay E, Sipka S, Gyimesi E, Csipo I, Szegedi G (1995) Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation 92:2969–2974PubMed Filep JG, Bodolay E, Sipka S, Gyimesi E, Csipo I, Szegedi G (1995) Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation 92:2969–2974PubMed
39.
go back to reference Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V et al (1995) Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 99:255–260CrossRefPubMed Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V et al (1995) Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 99:255–260CrossRefPubMed
40.
go back to reference Akazawa H, Ikeda U, Kuroda T, Shimada K (1996) Plasma endothelin-1 levels in Takayasu's arteritis. Cardiology 87:303–305PubMed Akazawa H, Ikeda U, Kuroda T, Shimada K (1996) Plasma endothelin-1 levels in Takayasu's arteritis. Cardiology 87:303–305PubMed
41.
go back to reference Pache M, Schwarz HA, Kaiser HJ, Wüest P, Klöti M, Dubler B, Flammer J (2002) Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med Sci Monit 8:CR616–CR619PubMed Pache M, Schwarz HA, Kaiser HJ, Wüest P, Klöti M, Dubler B, Flammer J (2002) Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med Sci Monit 8:CR616–CR619PubMed
Metadata
Title
A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis
Authors
Anna Kuryliszyn-Moskal
Piotr Adrian Klimiuk
Stanisław Sierakowski
Mariusz Ciolkiewicz
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0007-2

Other articles of this Issue 3/2006

Clinical Rheumatology 3/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.